Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 May;39(5):1070–1076. doi: 10.1128/aac.39.5.1070

In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373.

K Bartizal 1, T Scott 1, G K Abruzzo 1, C J Gill 1, C Pacholok 1, L Lynch 1, H Kropp 1
PMCID: PMC162685  PMID: 7625791

Abstract

Lipopeptide L-733560 is a hybrid analog of L-731373 and L-705589. All are water-soluble semisynthetic pneumocandin Bo derivatives. In vitro susceptibility testing of L-705589, L-731373, and L-733560 against more than 200 clinical isolates consisting of eight Candida species, Cryptococcus neoformans, and three Aspergillus species was performed by the broth microdilution methods. All three pneumocandins exhibited potent anti-Candida activity and moderate anti-C. neoformans activity. However, anti-Aspergillus activity was demonstrated only by an agar disk diffusion method. Antifungal agent-resistant Candida species and C. neoformans showed susceptibility comparable to that of susceptible isolates. Growth inhibition kinetic studies against Candida albicans revealed fungicidal activity within 3 to 5 h. Drug combination studies with pneumocandins and amphotericin B revealed indifferent activity against C. albicans and additive effects against C. neoformans and Aspergillus fumigatus. The activities of the compounds were not dramatically affected by the presence of serum. Resistance induction studies showed that the susceptibility of C. albicans MY1055 was not significantly altered by repeated exposure to subinhibitory concentrations of L-733560. Erythrocyte hemolysis studies indicated minimal hemolytic potential with pneumocandins. Results from preclinical evaluations and development studies performed thus far indicate that the pneumocandins should be safe, broad-spectrum fungicidal agents and potent parenteral antifungal agents.

Full Text

The Full Text of this article is available as a PDF (204.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abruzzo G. K., Flattery A. M., Gill C. J., Kong L., Smith J. G., Krupa D., Pikounis V. B., Kropp H., Bartizal K. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 1995 May;39(5):1077–1081. doi: 10.1128/aac.39.5.1077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anaissie E. J., Bodey G. P., Rinaldi M. G. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis. 1989 Apr;8(4):323–330. doi: 10.1007/BF01963467. [DOI] [PubMed] [Google Scholar]
  3. Anaissie E., Bodey G. P., Kantarjian H., Ro J., Vartivarian S. E., Hopfer R., Hoy J., Rolston K. New spectrum of fungal infections in patients with cancer. Rev Infect Dis. 1989 May-Jun;11(3):369–378. doi: 10.1093/clinids/11.3.369. [DOI] [PubMed] [Google Scholar]
  4. Bartizal K., Abruzzo G., Trainor C., Krupa D., Nollstadt K., Schmatz D., Schwartz R., Hammond M., Balkovec J., Vanmiddlesworth F. In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother. 1992 Aug;36(8):1648–1657. doi: 10.1128/aac.36.8.1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beaulieu D., Tang J., Zeckner D. J., Parr T. R., Jr Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase. FEMS Microbiol Lett. 1993 Apr 1;108(2):133–137. doi: 10.1111/j.1574-6968.1993.tb06088.x. [DOI] [PubMed] [Google Scholar]
  6. Boken D. J., Swindells S., Rinaldi M. G. Fluconazole-resistant Candida albicans. Clin Infect Dis. 1993 Dec;17(6):1018–1021. doi: 10.1093/clinids/17.6.1018. [DOI] [PubMed] [Google Scholar]
  7. Bouffard F. A., Zambias R. A., Dropinski J. F., Balkovec J. M., Hammond M. L., Abruzzo G. K., Bartizal K. F., Marrinan J. A., Kurtz M. B., McFadden D. C. Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem. 1994 Jan 21;37(2):222–225. doi: 10.1021/jm00028a003. [DOI] [PubMed] [Google Scholar]
  8. Espinel-Ingroff A., Kish C. W., Jr, Kerkering T. M., Fromtling R. A., Bartizal K., Galgiani J. N., Villareal K., Pfaller M. A., Gerarden T., Rinaldi M. G. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 1992 Dec;30(12):3138–3145. doi: 10.1128/jcm.30.12.3138-3145.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Galgiani J. N., Reiser J., Brass C., Espinel-Ingroff A., Gordon M. A., Kerkering T. M. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother. 1987 Sep;31(9):1343–1347. doi: 10.1128/aac.31.9.1343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Guiot H. F., Fibbe W. E., van 't Wout J. W. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis. 1994 Apr;18(4):525–532. doi: 10.1093/clinids/18.4.525. [DOI] [PubMed] [Google Scholar]
  11. Hector R. F. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev. 1993 Jan;6(1):1–21. doi: 10.1128/cmr.6.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hitchcock C. A., Pye G. W., Troke P. F., Johnson E. M., Warnock D. W. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother. 1993 Sep;37(9):1962–1965. doi: 10.1128/aac.37.9.1962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Huang A., Edwards F., Bernard E. M., Armstrong D., Schmitt H. J. In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis. 1990 Sep;9(9):697–699. doi: 10.1007/BF01964276. [DOI] [PubMed] [Google Scholar]
  14. James P. G., Cherniak R., Jones R. G., Stortz C. A., Reiss E. Cell-wall glucans of Cryptococcus neoformans Cap 67. Carbohydr Res. 1990 Apr 2;198(1):23–38. doi: 10.1016/0008-6215(90)84273-w. [DOI] [PubMed] [Google Scholar]
  15. Kobayashi G. S., Spitzer E. D. Testing of organisms for susceptibility to triazoles: is it justified? Eur J Clin Microbiol Infect Dis. 1989 May;8(5):387–389. doi: 10.1007/BF01964051. [DOI] [PubMed] [Google Scholar]
  16. Komshian S. V., Uwaydah A. K., Sobel J. D., Crane L. R. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989 May-Jun;11(3):379–390. doi: 10.1093/clinids/11.3.379. [DOI] [PubMed] [Google Scholar]
  17. Kurtz M. B., Douglas C., Marrinan J., Nollstadt K., Onishi J., Dreikorn S., Milligan J., Mandala S., Thompson J., Balkovec J. M. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother. 1994 Dec;38(12):2750–2757. doi: 10.1128/aac.38.12.2750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kurtz M. B., Heath I. B., Marrinan J., Dreikorn S., Onishi J., Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother. 1994 Jul;38(7):1480–1489. doi: 10.1128/aac.38.7.1480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pfaller M. A. Epidemiology and control of fungal infections. Clin Infect Dis. 1994 Aug;19 (Suppl 1):S8–13. doi: 10.1093/clinids/19.supplement_1.s8. [DOI] [PubMed] [Google Scholar]
  20. Ruhnke M., Eigler A., Tennagen I., Geiseler B., Engelmann E., Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol. 1994 Sep;32(9):2092–2098. doi: 10.1128/jcm.32.9.2092-2098.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Swartz M. N. Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2420–2427. doi: 10.1073/pnas.91.7.2420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Swerdloff J. N., Filler S. G., Edwards J. E., Jr Severe candidal infections in neutropenic patients. Clin Infect Dis. 1993 Nov;17 (Suppl 2):S457–S467. doi: 10.1093/clinids/17.supplement_2.s457. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES